1,379 assets in Cancer

Therapeutic assets addressing Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
km257 bispecific antibody Cancer	Xuanzhu Biopharmaceutical Co., Ltd.	P1	NR ()
km501 Cancer	Xuanzhu Biopharmaceutical Co., Ltd.	P1	NR ()
km602 Cancer	Xuanzhu Biopharmaceutical Co., Ltd.	P1	NR ()
Lbl-024 For Cancer	Nanjing Leads Biolabs Co.,Ltd	P2	NR ()
lcb02a Cancer	LigaChem Biosciences, Inc.	P1/2	NR ()
LNF2105 Cancer	Shandong New Time Pharmaceutical Co., LTD	P1	NR ()
Mrna-Lnp Cancer	IntraAb, Inc.	P1/2	NR ()
nb002 Cancer	Suzhou Neologics Bioscience Co., Ltd.	P1	NR ()
nm6603 Cancer	NucMito Pharmaceuticals Co. Ltd.	P1	NR ()
Onc-783 Cancer	OncoC4, Inc.	P1	NR ()
qlh11906 Cancer	Qilu Pharmaceutical Co., Ltd.	P1	NR ()
qlm2011 Cancer	Qilu Pharmaceutical (Hainan) Co., Ltd.	P1	NR ()
qls1209 Cancer	Qilu Pharmaceutical Co., Ltd.	P1	NR ()
qls5133 Cancer	Qilu Pharmaceutical Co., Ltd.	P1/2	NR ()
R-Star001 Cancer	changjianhua	P1	NR ()
Shr-9803 Cancer	Jiangsu HengRui Medicine Co., Ltd.	P1/2	NR ()
SIM0689 Cancer	Jiangsu Simcere Pharmaceutical Co., Ltd.	P1	NR ()
skb118 Cancer	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	P1/2	NR ()
skb565 Cancer	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	P1/2	NR ()
Sk-Nk Cancer	Tianjin Medical University Cancer Institute and Hospital	P1/2	NR ()
Ssgj-706 Cancer	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	P1	NR ()
sys6006 Cancer	CSPC Megalith Biopharmaceutical Co.,Ltd.	P1/2	NR ()
sys6051 Cancer	CSPC Megalith Biopharmaceutical Co.,Ltd.	P1	NR ()
trx103 Cancer	Tr1X, Inc.	P1	NR ()
xnw34017 Cancer	Evopoint Biosciences Inc.	P1/2	NR ()
yb1-x7 Cancer	Shanghai Salvectors Biotechnology LTD.	N/A	NR ()
yk0901 cells Cancer	Peking University	P1	NR ()
yy2201 Cancer	Jiangsu YaYao Biotechnology Co., Ltd.	Early P1	NR ()
zl-85fa tablets Cancer	Chengdu Zenitar Biomedical Technology Co., Ltd	P1/2	NR ()

Showing 1351 to 1379 of 1,379 assets

PreviousPage 28 of 28Next